| Literature DB >> 28866751 |
D Januś1,2, M Wójcik3,4, G Drabik5, Ł Wyrobek6, J B Starzyk3,4.
Abstract
BACKGROUND: The prevalence of autoimmune thyroiditis (AIT) and papillary thyroid carcinoma (PTC) is rising in children and adolescents, and the coincidence of AIT and PTC is as high as 6.3-43%.Entities:
Keywords: Autoimmune thyroiditis; Normoechogenic thyroid background; Normoechogenic thyroid parenchyma; Papillary thyroid carcinoma; aTG; aTPO
Mesh:
Year: 2017 PMID: 28866751 PMCID: PMC5823967 DOI: 10.1007/s40618-017-0758-z
Source DB: PubMed Journal: J Endocrinol Invest ISSN: 0391-4097 Impact factor: 4.256
Fig. 1a, b Diffuse thyroiditis with hypoechogenic background and normoechogenic parenchyma, c, d diffuse thyroiditis with irregular background
Fig. 2Nodular AIT variants with normoechogenic irregular background with PTC development. a, b Axial planes of thyroid gland of 17-year-old girl; c longitudinal plane of thyroid gland of 11-year-old boy; d an axial plane of thyroid gland of 18-year-old girl; e, f axial and longitudinal planes of thyroid gland of 17-year-old girl
Fig. 3Nodular AIT variants with normoechogenic irregular background with PTC development. a, b Axial planes of thyroid gland of 18-year girl; c axial and longitudinal plane of thyroid gland of 14.5-year-old girl; d an axial plane of thyroid gland of 14-year-old girl; e, f axial and longitudinal planes of thyroid gland of 13-year-old boy with diffuse sclerosing variant of PTC
Fig. 4a, b AIT variant with micronodulations; c, d AIT variant with diffuse hypoechogenic background
Thyroid status in different variants of AIT (*p < 0.05 vs diffuse thyroiditis with hypoechogenic background and normoechogenic parenchyma variant with hypothyreosis)
| Ultrasound pattern of the thyroid gland | Diffuse thyroiditis with hypoechogenic background and normoechogenic parenchyma | Diffuse thyroiditis with irregular background | Nodular variant and normoechogenic irregular background | Micronodulations | Diffuse hypoechogenic background | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 63 (35.2%) | 54 (30.2%) | 34 (18.9%) | 21 (11.7%) | 7 (3.9%) | ||||||||
| TSH mean [range] uIU/ml ( | 62.2 (0.005–692.3) | 5.58 (0.001–61.7) | 8.5 (0.02–98.91) | 16.8 (0.02–248.9) | 5.04 (2.04–16) | ||||||||
| Thyroid status | T | E | H | T | E | H | T | E | H | T | E | H | E |
|
| 8 (12.7%) | 11 (17.5%) | 44 (69.8%) | 15 (27.8%) | 19 (35.2%) | 20 37%) | 4 (11.8%) | 18 (52.9%) | 12 (35.3%) | 1 (4.8%) | 11 (52.4%) | 9 (42.8%) | 7 |
| Compensated | – | – | 18 (40.9%) | – | – | 11 (55%) | – | – | 10 (83.3%) | – | – | 7 (77.8%) | – |
| Overt | 8 | – | 26 (59.1%) | 15 | – | 9 (45%) | 4 | – | 2 (16.7%) | 1 | – | 2 (22.2%) | – |
| Age years | 14.7 (2.7) | 14.9 (2.4) | 12.8 (2.9) | 13.9 (4.1) | 14.8 (1.9) | 13.0 (3.3) | 16.2 (2.9) | 15.2 (3.0) | 12.7 (2.9) | 10.0 | 14.9 (2.8) | 14.1 (1.6) | 13.1 3.6) |
| TSH uIU/ml ( | 0.01 (0.0) | 3.6 (1.1) | 88.1 (153.1) | 0.1 (0.2) | 2.8 (1.0) | 12.7 (12.5) | 0.2 (0.4) | 2.7 (1.2) | 20.0 (26.5) | 0.02 | 2.4 (1.1 | 36.3 (79.9) | 5.0 (5.4) |
| fT3 pmol/l (n: 3.6–6.8) | 27.1 (7.1) | 5.4 (0.9) | 4.5 (1.6) | 17.5 (8.6) | 5.3 (1.1) | 5.1 (2.1) | 15.4 (7.6) | 5.6 (0.7) | 56 (1.3) | 30.8 | 5.4 (0.5) | 4.4 (0.6) | 5.2 (0.6) |
| fT4 pmol/l ( | 45.3 (31.0) | 13.9 (2.4) | 9.9 (5.1) | 38.5 (21.9) | 13.5 (3.7) | 12.4 (3.9) | 30.6 (13.1) | 14.7 (3.9) | 11.7 (4.9) | 52.0 | 11.8 (5.7) | 10.9 (5.0) | 13.2 (1.9) |
| aTPO IU/ml ( | 3572.3 (2757.5) | 5467.2 (3615.3) | 6041.9 (3526.2) | 3040.8 (2792.8)* | 1245.5 (1048.4)* | 1471.9(1704.0)* | 749.5 (1059.2) | 1825.7 (2645.7)* | 2719.5 (3340.9)* | 770 | 1617.6 (1976.5)* | 1922.5 (1670.7)* | 487.3 (660.6) |
| aTG U/ml ( | 387.8 (711.8) | 829.6 (1148.4) | 1880.5 (3082.3) | 556.0 (1585.4)* | 233.2 (353.9)* | 256.9 (415.2)* | 49.2 (26.6) | 177.7 (216.1)* | 384.3 (549.9)* | 227.2 | 634.8 (1484.1)* | 1030.5 (2200.2)* | 142.9 (133.7) |
| TRAB U/ml ( | 11.1 (7.7) | 0.6 (0.5) | 1.0 (0.6) | 7.9 (7.9) | 0.9 (0.2) | 0.9 (0.5) | 6.8 (2.9) | 1.1 (1.1) | 1.3 (0.8) | 5.8 | 0.9 (0.1) | 4.2 (04.5) | 1.2 |
| PTC | – | – | – | – | – | – | 1 (25%) | 5 (27.8%) | 2 (16.6%) | – | – | – | |
T hyperthyroid, E euthyroid, H hypothyroid. Data are expressed as mean (SD)
Characteristics of PTC patients
| Patients | Age yrs | Cause of referral | Nodule size (mm) | TNM | PTC variant | 131 J | aTPO IU/ml | aTG U/ml | TRAb IU/l | TSH uIU/ml N:0.4–4.0 | aTg after surgery |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AACE/ACE/AME Risk group | ATA risk group | ||||||||||
| 2a,2b | 16 | Goiter | 6 | PT1aN0M0 | Classic | − | 5911.2 | 300 | – | 2.12 | <20 |
| Class 2 | I | ||||||||||
| 2c | 11 | Goiter | 12 | pT1bN0M0 | Follicular with capsule | − | 42.94 | 43.39 | – | 2.01 | <20 |
| Class 2 | I | ||||||||||
| 2d | 18 | Goiter | 13 | pT1bN0M0 | Classic | + | <30 | <20 | 5.2 | 0.02 | <20 |
| Class 3 | I | ||||||||||
| 2e,2f | 17 | Nodule found on US | 10 | pT1aN0M0 | Classic | − | 1271.7 | – | – | 5.01 | <20 |
| Class 3 | I | ||||||||||
| 3a,3b | 17 | Nodule found on US | 21 × 16 × 26 | PT2N1bM0 | Follicular | + | 853.4 | – | 0.7 | 1.02 | <20 |
| Class 3 | II | ||||||||||
| 3c | 13 | Goiter | 8 × 8 × 9 | PT1aN1aM0 | Classic/follicular | + | 126.2 | 154.3 | – | 5.05 | <20 |
| Class 3 | II | ||||||||||
| 3d | 14 | Nodule found on US | 7 and 2 | PT1aN0M0 | 7 mm-classic/solid; | − | 1300 | – | – | 4.8 | <20 |
| Class 3 | I | 2 mm-follicular | |||||||||
| 3e,3f | 13 | Lymph node enlargement | 23 | PT3N1bM1 | Diffuse sclerosing | + | >9000 | >8000 | 1.2 | 4.12 | <20 |
| Class 3 | III |
AACE/ACE/AME US classification system: Class 1-low-risk thyroid lesion; Class 2-intermediate-risk thyroid lesion, Class 3-high-risk thyroid lesion [29]. ATA pediatric risk group: I—low risk, II—intermediate risk, III—high risk [28]